No Picture
News

OTC Markets Group Grants Evofem Additional Time to File Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2022

SAN DIEGO, Dec. 29, 2022 /PRNewswire/ — Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that it has been granted additional time by the OTC Markets Group to file its Quarterly Report on Form 10-Q for […]

No Picture
News

Boundless Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference

SAN DIEGO–(BUSINESS WIRE)–Boundless Bio. a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that its Chief Executive Officer, Zachary Hornby, will present at the 41st […]

No Picture
News

Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors

SAN DIEGO–(BUSINESS WIRE)–Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated […]

No Picture
News

Neurocrine Biosciences Announces U.S. FDA Accepts Supplemental New Drug Application for Valbenazine as a Treatment for Chorea Associated with Huntington Disease

Prescription Drug User Fee Act (PDUFA) Target Action Date Set for August 20, 2023 SAN DIEGO, Dec. 22, 2022 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced that the […]

No Picture
News

Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023

SAN DIEGO–(BUSINESS WIRE)–Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 9:00 a.m. Pacific Time, followed by a question […]

No Picture
News

Angiocrine Bioscience Announces it has been awarded a $15M Grant from the California Institute for Regenerative Medicine for AB-205 Phase 3 Clinical Trial

Positively impact patients’ lives through the reparative powers of E-CEL® Therapies SAN DIEGO, Dec. 19, 2022 /PRNewswire/ — Angiocrine Bioscience, Inc., a clinical-stage biopharmaceutical company today announced that the California Institute for Regeneration Medicine (CIRM) […]

No Picture
News

#ASH22 Recap: Leading hematology experts talk top readouts; Fireside chat with Novo Nordisk’s Ludovic Helfgott; More

The American Society of Hematology wraps up every year with one of the biggest conferences in the biopharma industry. It’s a place where lots of new innovations in hematology — from leukemia to multiple myeloma […]

No Picture
News

QuidelOrtho and Runda Medical Form Joint Venture to Develop and Manufacture Assays for VITROS® Platform

SAN DIEGO–(BUSINESS WIRE)–QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho” or the “Company”), a global provider of innovative in vitro diagnostics (IVD) technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today the signing of a […]

No Picture
News

Equillium’s Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis

LA JOLLA, Calif.–(BUSINESS WIRE)—- $EQ–Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Biocon Limited, in collaboration with Equillium, has initiated […]